COMMUNIQUÉS West-GlobeNewswire

Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025
23/10/2025
LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at 8:30 a.m. Eastern [...]
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
23/10/2025
Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr. Mir Imran Each of Samsara and Anomaly [...]
Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third [...]
New Clinical Data Confirms Yomi® Robotic System Enhances Efficiency in Dental Implant Surgery
23/10/2025
MIAMI, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Neocis ® , the leader in robotic-assisted dental surgery, today announced new clinical data highlighting the significant efficiency benefits of its Yomi ® Robotic System, the [...]
Award-Winning Film An Inconvenient Study Sparks Global Debate on Vaccine Safety and Chronic Disease
23/10/2025
Following its viral global premiere, ICAN and Del Bigtree release a response to media criticisms of the unpublished vaccinated-versus-unvaccinated study featured in the film AUSTIN, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE [...]
Progyny, Inc. Announces Details for Its Third Quarter 2025 Results Report
23/10/2025
NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended September 30, [...]
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
23/10/2025
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer 64% overall [...]
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
23/10/2025
-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical data supports [...]
eteraflex connects and CliniExperts Announce Global Alliance to Redefine Clinical Research and Regulatory Services Delivery
23/10/2025
Princeton, NJ, Oct. 23, 2025 (GLOBE NEWSWIRE) -- eteraflex connects and CliniExperts have announced a strategic partnership that unites their complementary expertise in clinical research, regulatory strategy, and [...]
With Med4Cure, EUROAPI accelerates pharmaceutical innovation at the service of health sovereignty
23/10/2025
Press Release The project launch event, held at the Vertolaye site, brought together State officials, elected representatives, and several project partners to accelerate pharmaceutical innovation in Europe Paris – [...]
Avec Med4Cure, EUROAPI accélère l’innovation pharmaceutique au service de la souveraineté sanitaire
23/10/2025
Communiqué de presse L’événement inaugural de lancement du projet, organisé sur le site de Vertolaye, a réuni l’État, des élus et plusieurs partenaires pour accélérer l’innovation pharmaceutique en Europe Paris et [...]
Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croissance au 3ème trimestre 2025. Confirmation de l’ensemble des objectifs financiers 2025.
23/10/2025
Chiffre d’affaires au 30 septembre 2025 Retour de la croissance au 3 ème trimestre 2025 Chiffre d’affaires à 9 mois : 586,5 M€, en retrait de 2,8% à TCC 1 et périmètre comparable 2 , largement dû à la baisse de l’ [...]
Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025.
23/10/2025
Revenue at September 30, 2025 Return to growth in Q3 2025 9-month revenue: €586.5 million, down 2.8% at CER 1 and on a like-for-like basis 2 , largely due to the fall in activity in France An increase in Q3 of 2.6% at [...]
Instinct Science and Cornell University Hospital for Animals Modernize Veterinary Care with Instinct Treatment Plan
23/10/2025
PHILADELPHIA, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Instinct Science , a leading provider of clinical-grade software for veterinary hospitals, today announced that the Cornell University Hospital for Animals (CUHA) has [...]
Rentschler Biopharma Inc. named Manufacturer of the Year for Central Massachusetts
23/10/2025
Company honored by state’s Legislative Manufacturing Caucus for outstanding leadership and contributions to the manufacturing sector State -of-the-art production line is bringing in new clients, new projects, new [...]
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
23/10/2025
The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing advancement into Cohort 4 with a dose of 10 ug/kg/day Actively screening [...]
Global Drug Delivery Systems (DDS) Market Transforms Amid New Pharma Demands
23/10/2025
New Alira Health Report Reveals Digital and Sustainable Innovations Driving Drug Delivery Market FRAMINGHAM, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Alira Health today released its 2025 Global Drug Delivery System [...]
SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
23/10/2025
TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat [...]
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
23/10/2025
Consistency of BMD gains presented at NAMS 2025 demonstrate EB613’s efficacy in both young postmenopausal women and in women 10 years post-menopause Data further support EB613 potential as a first-in-class oral anabolic [...]

Pages